Loading...
XMEX
LABB
Market cap689mUSD
Oct 08, Last price  
12.79MXN
1D
-0.23%
1Q
-16.02%
Jan 2017
-40.57%
IPO
54.75%
Name

Genomma Lab Internacional SAB de CV

Chart & performance

D1W1MN
XMEX:LABB chart
P/E
7.78
P/S
0.71
EPS
1.64
Div yield, %
6.24%
Shrs. gr., 5y
-0.76%
Rev. gr., 5y
4.81%
Revenues
17.54b
-5.73%
1,373,480,0001,872,863,0002,629,430,0004,424,655,0006,263,621,0008,074,787,0009,799,690,00011,360,689,00011,540,998,00011,042,452,00011,316,310,00012,078,443,00011,794,419,00012,712,890,00013,870,148,00015,487,059,00016,819,912,00016,467,126,00018,606,903,00017,541,158,000
Net income
1.61b
+7.65%
180,301,000304,399,000515,776,000760,036,0001,092,958,0001,415,954,0001,504,004,0001,760,607,0001,444,558,000-1,068,519,000-1,680,925,0001,279,208,0001,109,465,000764,463,0001,403,503,0001,307,867,0001,389,203,0001,084,915,0001,493,122,0001,607,387,000
CFO
2.05b
-32.28%
-101,407,000103,331,000228,892,000385,519,000849,667,00089,212,000-107,086,0001,870,747,0001,038,596,000322,300,0001,674,845,0001,420,074,0001,562,479,0001,006,931,0001,714,525,0001,468,351,0002,054,793,0002,247,012,0003,033,717,0002,054,539,000
Dividend
Sep 29, 20260.2 MXN/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Genomma Lab Internacional, S.A.B. de C.V., alongside its various operating units, specializes in the creation, promotion, and distribution of a wide array of over-the-counter (OTC) pharmaceutical goods and personal care items. Its operations span across Mexico and numerous international markets. The company's extensive product portfolio addresses diverse consumer needs, encompassing categories such as skincare, hair care, general health and wellness solutions, and pain management. Specific offerings include remedies for coughs and colds, digestive health aids, sexual well-being products, antiperspirants and deodorants, hand sanitizers, isotonic beverages, and shaving essentials. Beyond these, it also markets specialized pharmaceuticals such as analgesics, antifungals, and treatments for hemorrhoids. These products are brought to market under a multitude of well-known brands, including Cicatricure, Asepxia, Teatrical, Goicoechea, Sistema GB, Medicasp, Tío Nacho, Vanart, Novamil, Ultra Bengue, X-Ray, Tafirol, Alliviax, Bufferin, Next, XL-3, Genoprazol, QG5, Kaopectate, Proctan, Nikzon, Unesia, Silka Medic, lagicam, Suerox, Groomen, DiabetTX, among others. Established in 1996, Genomma Lab Internacional, S.A.B. de C.V. maintains its corporate headquarters in Mexico City, Mexico.

Key people

Jorge Luis Brake Valderrama
Chief Executive Officer · since 2018
Cesar Alejandro Jaramillo Lopez
Vice President of Global Marketing · since 2018
Santiago Velez Pelaez
Vice President of Industrial and Research and Development · since 2018
Antonio Zamora Galland
Chief Financial Officer, Chief Administrative Officer, Vice President · since 2018
Leticia Campos Herrera
Global Director of Human Resources (Genomma Experience) · since 2018
Sabrina Lucila Herrera Aspra
Director · since 2017
Hector Carrillo Gonzalez
Independent Director
Scott R. Emerson
Independent Director · since 2015
Juan Carlos Gavito
Independent Director
Independent Director
Ignacio Gonzalez Rodriguez
Independent Director
Javier Vale Castilla
Independent Director · since 2016
Independent Director · since 2018
IPO date
Jun 19, 2008
Employees
2,388
Domiciled in
MX
Incorporated in
MX

Valuation

Title
MXN in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT